In our recently published work, we screened several melanoma and carcinoma cell lines (MV3, SCL‐1, SCL‐2, BLM, patient‐derived HNC cells) and targets (MCSP, EpCAM, cell surface vimentin) to find a suitable candidate for the testing of microfluidic platforms. This evidence concerns the gene VIM and carcinoma.